Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

as of end-April 2013.  Senomyx's partners for this program are exploring further opportunities to expand their customer bases and increase the number of product offerings.

Bitter Blockers Program:  Senomyx's Bitter Blockers are intended to reduce or block bitter taste and to improve the overall taste characteristics of foods, beverages, and ingredients.  During the fourth quarter of 2012, Senomyx announced that a Company partner had initiated its first market launch of a retail product incorporating S6821 in a country in Southeast Asia.  Marketing is continuing and the partner is currently evaluating the use of S6821 in additional products and geographies.  S6821 has demonstrated activity against bitter-tasting ingredients such as soy and whey proteins, menthol, caffeine, cocoa, and Rebaudioside A (stevia), which are used in foods and beverages.Discovery & Development Program Updates: Sweet Taste Program:  Senomyx is conducting development activities in support of regulatory filings for S617, a unique new flavor modifier intended to be used to restore the desired taste profile of products in which either high fructose corn syrup (HFCS) or sucrose has been reduced.  Taste tests have demonstrated that S617 allows a very meaningful reduction of HFCS and sucrose in product prototypes while maintaining the desired sweet taste.  Evaluations of S617 in a variety of products of interest are underway.  Definitive safety studies, as well as additional regulatory-focused activities, are ongoing.  In addition, Senomyx is continuing to optimize multiple potential new sweet flavor modifiers that have desirable properties for restoring the flavor profile in reduced-sweetener products.

The goal of the Natural High Intensity Sweetener component of Senomyx's Sweet Taste Program is to discover and develop novel no- or low-calorie natural high intensity sweeteners.  The Company continues to make good progr
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 E-QURE Corp. (OTCQB: ... its Bio-electrical Signal Therapy device ("BST Device"), a new ... to heal chronic wounds, today announced that the Company ... Israeli distributor specializing in medical devices, for the marketing ... is a 70 years old, sales, marketing and distribution ...
(Date:7/31/2015)... , July 31, 2015 In ... resources that help them drive positive health outcomes, ... vital source of patient care in their communities. ... annual tradeshow and conference, AmerisourceBergen announced a new ... Pharmacy Services Administration Organization and help independent pharmacies ...
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... Transposagen Biopharmaceuticals, Inc . ... genetic modification technology, have announced a non-exclusive marketing and distribution ... ™ technology. The piggyBac ... Modification System enables researchers to: Alter the ...
... CARLSBAD, Calif., May 11, 2011 Life Technologies Corporation ... that over 3,800 of its employees worldwide are scheduled to ... benefit their communities as part of the company,s eighth annual ... than 15,000 hours of community service at 48 sites in ...
... Technologies, Inc. today announced that positive preclinical data ... Paris, France on May 18, 2011 in a ... DES with a Fully-absorbable Coating and Enhanced Drug ... ("MiStent DES") is an ultra-thin, advanced alloy drug-eluting ...
Cached Biology Technology:Transposagen's piggyBac™ Vectors to be Distributed by System Biosciences 2Transposagen's piggyBac™ Vectors to be Distributed by System Biosciences 3Life Technologies Employees 'Give Back' to Their Communities During Eighth Annual Global Volunteer Day 2Life Technologies Employees 'Give Back' to Their Communities During Eighth Annual Global Volunteer Day 3Life Technologies Employees 'Give Back' to Their Communities During Eighth Annual Global Volunteer Day 4Life Technologies Employees 'Give Back' to Their Communities During Eighth Annual Global Volunteer Day 5Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR 2Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR 3
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... nine out of 10 new cancer drugs successfully ... in human clinical testing. A new partnership facilitated ... outcome. The partnership brings together The UC ... National Cancer Institute,s (NCI) Center for Advanced Preclinical ...
... image shows the huge plume of sulphur dioxide that spewed ... Andes about 600 km south of Santiago. After lying ... earthquakes signalled the beginnings of this major volcanic eruption. On ... volcanic ash and gas over 10 km high. ,Several thousand ...
... Bethesda, MD The Federation of American Societies ... its newest client, the International Conference on Human Immunity ... Emory Conference Center in Atlanta, Georgia, on April 13-14, ... provide meeting management services. One of the organizers, ...
Cached Biology News:NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials 2NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials 3
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
Biology Products: